Key Highlights:
- AstraZeneca Pharma India has received permission from the Central Drugs Standard Control Organisation to import and market Imfinzi (durvalumab solution for infusion 120 mg/2.4 mL and 500 mg/10 mL) in India for an additional oncology indication.
- Under the approval, Durvalumab in combination with carboplatin and paclitaxel is indicated for the first-line treatment of adults with primary advanced or recurrent Endometrial Cancer who are eligible for systemic therapy, followed by maintenance treatment with durvalumab monotherapy in patients with mismatch repair–deficient disease.
- The approval allows the company to market the therapy in India for the specified indication, subject to additional statutory clearances if required, expanding treatment options for patients with advanced endometrial cancer.
Implications:
Imfinzi storms endometrial cancer protocols, giving oncologists a potent immunotherapy combo that leapfrogs chemo-only standards.
AstraZeneca doubles down on gynecologic oncology dominance, stealing share from Roche while hospitals race to adopt dMMR testing.
Dual gastric/endometrial wins cement AstraZeneca’s solid tumor leadership as immunotherapy reshapes advanced cancer care.
Source: Expresspharma | Image: AstraZeneca
No Comment! Be the first one.